Media Advisory - Oncolytics Biotech Inc. to Present at BIO Investor Forum 2008.
CALGARY, Oct. 21 /PRNewswire-FirstCall/ -- Dr. Brad Thompson, President and CEO of Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY), will present a corporate overview of the Company at the 7th Annual BIO Investor Forum 2008 on Wednesday, October 29, 2008 at 2:15 p.m. PT. The conference will be held...

The IMF Recognizes Nobel Prize Winner.
HEALTH AND BEAUTY CLOSE-UP-13 October 2008-The IMF Recognizes Nobel Prize Winner(C)2008 - CloseUpMedia - newsdesk@closeupmedia.com The International Myeloma Foundation (IMF) - supporting research and providing education, advocacy, and support for myeloma patients, families, researchers, and physicians - congratulated French researcher Dr. Luc Montagnier as co-recipient of the...

Immigrants must get HPV vaccine.
Young women seeking to immigrate to the United States currently are required to be vaccinated against the human papillomavirus, under an amendment to the Immigration and Nationality Act. Under the 1996 amendment, individuals seeking immigrant visas must provide proof of vaccination for all vaccines recommended by the U.S. Advisory...

Idenix Pharmaceuticals to Present at Needham & Company's Focus on Infectious Disease Investor Day.
CAMBRIDGE, Mass., Nov. 14 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. announced today that Idenix management will present a corporate overview at Needham & Company's Focus on Infectious Disease Investor Day on Thursday, November 20, 2008 at 9:00 a.m. ET at the Needham & Company Headquarters in New York, NY. ...

InterMune to Present at Lazard Capital Markets Healthcare Conference.
BRISBANE, Calif., Nov. 14 /PRNewswire-FirstCall/ -- InterMune, Inc. today announced that Daniel G. Welch, Chairman, Chief Executive Officer and President of InterMune, will present at Lazard Capital Markets 5th Annual Healthcare Conference on November 18, 2008 at 3:10 p.m. EST. To access a live audio webcast of...

Oncolytics Biotech Inc. Collaborators to Present REOLYSIN(R) Research at CTOS Annual Meeting.
CALGARY, Nov. 14 /PRNewswire-FirstCall/ -- Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) announced today that a poster presentation authored by Dr. Anders Kolb of the Nemours Center for Childhood Cancer Research entitled "Systemic Administration of REOLYSIN Inhibits Growth of Human Sarcoma Xenografts Alone and in Combination with Cisplatin and...

Eliminating viral reservoirs key to curing HIV.
MEXICO CITY -- A cure for HIV infection will require identifying and eliminating reservoirs of silent HIV in the body, in addition to using highly active antiretovital therapy to stop viral replication. "It's 11 years since the introduction of HAART. The dramatic reductions in viremia seen in...

SteelKor, LLC Signs Joint Marketing Agreement With Makers of Fit(R) Fruit and Vegetable Wash to Launch Next Generation Produce Safety System.
ST. LOUIS, Oct. 22 /PRNewswire/ -- SteelKor, LLC ("SteelKor") today announced that they have signed a joint marketing agreement with HealthPro Brands, Inc. ("HealthPro"), makers of Fit Fruit & Vegetable Wash, to introduce the newest system in the fight against food-borne illness outbreaks linked to produce. SteelKor's expertise in...

Oncolytics Biotech Inc. Collaborators to Present Combination REOLYSIN(R) and Docetaxel Results at iSBTc Annual Meeting.
CALGARY, Oct. 23 /PRNewswire-FirstCall/ -- Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) announced today that an abstract entitled "A Phase I Study to Evaluate Systemic Wild-Type Reovirus (REOLYSIN(R)) in Combination with Docetaxel in Patients with Advanced Malignancies" will be available in the November/December issue of the Journal of Immunotherapy,...

The molecular basis of vulnerable plaque: potential therapeutic role for immunomodulation.
PURPOSE OF REVIEW: Athero-sclerosis is a chronic inflammatory/immune disease involving multiple cell types including monocytes-macrophages, T-lymphocytes, mast cells, and endothelial cells. Through recent studies the role of the immune system on development of atherosclerosis and approaches to modulate this response are being elucidated. RECENT FINDINGS: The use of statins,...